Veru Inc (VERU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Veru Inc (VERU) has a cash flow conversion efficiency ratio of -0.166x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.17 Million) by net assets ($37.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Veru Inc - Cash Flow Conversion Efficiency Trend (1990–2025)
This chart illustrates how Veru Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Veru Inc debt and liabilities for a breakdown of total debt and financial obligations.
Veru Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Veru Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MUI Properties Bhd
KLSE:3913
|
0.757x |
|
Oncopeptides AB
ST:ONCO
|
-23.926x |
|
Biohit Oyj B
HE:BIOBV
|
0.040x |
|
Milux Corporation Bhd
KLSE:7935
|
0.023x |
|
Hipay Group SA
PA:ALHYP
|
0.066x |
|
OTRS AG
F:TR9
|
0.155x |
|
Elliptic Laboratories AS
OL:ELABS
|
-0.017x |
|
Sol Strategies Inc. Common Shares
NASDAQ:STKE
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Veru Inc (1990–2025)
The table below shows the annual cash flow conversion efficiency of Veru Inc from 1990 to 2025. For the full company profile with market capitalisation and key ratios, see Veru Inc (VERU) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $18.33 Million | $-30.04 Million | -1.639x | -144.25% |
| 2024-09-30 | $32.32 Million | $-21.68 Million | -0.671x | +85.00% |
| 2023-09-30 | $19.68 Million | $-88.01 Million | -4.473x | -679.55% |
| 2022-09-30 | $82.80 Million | $-47.51 Million | -0.574x | -461.16% |
| 2021-09-30 | $152.29 Million | $-15.57 Million | -0.102x | -59.51% |
| 2020-09-30 | $30.11 Million | $-1.93 Million | -0.064x | +62.22% |
| 2019-09-30 | $32.33 Million | $-5.49 Million | -0.170x | +56.68% |
| 2018-09-30 | $29.48 Million | $-11.55 Million | -0.392x | -2030.67% |
| 2017-09-30 | $48.45 Million | $982.89K | 0.020x | +140.15% |
| 2016-09-30 | $33.93 Million | $-1.71 Million | -0.051x | -8.09% |
| 2015-09-30 | $33.13 Million | $-1.55 Million | -0.047x | -135.79% |
| 2014-09-30 | $28.07 Million | $3.67 Million | 0.131x | -65.22% |
| 2013-09-30 | $31.40 Million | $11.79 Million | 0.376x | -12.18% |
| 2012-09-30 | $24.22 Million | $10.36 Million | 0.428x | +2.81% |
| 2011-09-30 | $16.75 Million | $6.97 Million | 0.416x | +68.09% |
| 2010-09-30 | $16.13 Million | $3.99 Million | 0.247x | -44.22% |
| 2009-09-30 | $12.95 Million | $5.75 Million | 0.444x | +1.48% |
| 2008-09-30 | $9.71 Million | $4.24 Million | 0.437x | +7842.94% |
| 2007-09-30 | $7.45 Million | $-42.05K | -0.006x | -110.06% |
| 2006-09-30 | $4.77 Million | $267.94K | 0.056x | +193.26% |
| 2005-09-30 | $3.31 Million | $-199.26K | -0.060x | +49.30% |
| 2004-09-30 | $1.83 Million | $-216.76K | -0.119x | -120.19% |
| 2003-09-30 | $493.13K | $290.01K | 0.588x | +197.89% |
| 2002-09-30 | $630.28K | $-378.65K | -0.601x | +94.97% |
| 2001-09-30 | $52.32K | $-625.02K | -11.945x | -902.35% |
| 2000-09-30 | $-693.07K | $-1.03 Million | 1.489x | +190.28% |
| 1999-09-30 | $1.72 Million | $-2.84 Million | -1.649x | -75.79% |
| 1998-09-30 | $2.93 Million | $-2.75 Million | -0.938x | +40.55% |
| 1997-09-30 | $3.55 Million | $-5.61 Million | -1.578x | -192.58% |
| 1996-09-30 | $7.55 Million | $-4.07 Million | -0.539x | +10.89% |
| 1995-09-30 | $7.60 Million | $-4.60 Million | -0.605x | +0.17% |
| 1994-09-30 | $12.70 Million | $-7.70 Million | -0.606x | -1403.54% |
| 1993-09-30 | $4.30 Million | $200.00K | 0.047x | +112.79% |
| 1992-09-30 | $5.50 Million | $-2.00 Million | -0.364x | -55.37% |
| 1991-09-30 | $4.70 Million | $-1.10 Million | -0.234x | -583.69% |
| 1990-09-30 | $6.20 Million | $300.00K | 0.048x | -- |
About Veru Inc
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosa… Read more